PT - JOURNAL ARTICLE AU - Mutz, Julian AU - Wong, Win Lee Edwin AU - Powell, Timothy R. AU - Young, Allan H. AU - Dawe, Gavin S. AU - Lewis, Cathryn M. TI - The duration of lithium use and biological ageing: telomere length, frailty, metabolomic age and all-cause mortality AID - 10.1101/2023.12.18.23300105 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.18.23300105 4099 - http://medrxiv.org/content/early/2023/12/18/2023.12.18.23300105.short 4100 - http://medrxiv.org/content/early/2023/12/18/2023.12.18.23300105.full AB - Background Lithium is an established first-line treatment for bipolar disorder. Beyond its therapeutic effect as a mood stabiliser, lithium exhibits potential anti-ageing effects. This study aimed to examine the relationship between the duration of lithium use, biological ageing and mortality.Methods The UK Biobank is an observational study of middle-aged and older adults. We tested associations between the duration of lithium use (number of prescriptions, total duration of use, and duration of the first prescription period) and telomere length, frailty, metabolomic age, pulse rate and all-cause mortality.Results 591 individuals (mean age = 57.49 years; 55% females) had been prescribed lithium. There was no evidence that the number of prescriptions (β = −0.022, 95% CI −0.081 to 0.037, p = 0.47), the total duration of use (β = −0.005, 95% CI −0.023 to 0.013, p = 0.57) or the duration of the first prescription period (β = −0.018, 95% CI −0.051 to 0.015, p = 0.29) correlated with telomere length. There was also no evidence that the duration of lithium use correlated with frailty or metabolomic age. However, a higher prescription count or a longer duration of use was associated with a lower pulse rate. The duration of lithium use did not predict mortality.Conclusions We observed no evidence of associations between the duration of lithium use and biological ageing markers, including telomere length. Our findings suggest that the potential anti-ageing effects of lithium do not differ by duration of use.Competing Interest StatementAHY declares the following: paid lectures and advisory boards for companies with drugs used in affective and related disorders (Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage and Neurocentrx); principal investigator in the Restore-Life VNS registry study funded by LivaNova; principal investigator on "ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression"; principal investigator on "The Effects of Psilocybin on Cognitive Function in Healthy Participants"; principal investigator on "The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)"; principal investigator on "A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy" (Janssen); principal investigator on "An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD)" (Janssen); principal investigator on "A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy"; principal investigator on "A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR" (Janssen); UK chief investigator for Compass COMP006 & COMP007 studies; UK chief investigator for Novartis MDD study MIJ821A12201; grant funding (past and present) from NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research Institute (USA), MRC (UK), Wellcome Trust (UK), Royal College of Physicians (Edin), BMA (UK), UBC-VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund (Canada), MSFHR (Canada), NIHR (UK), Janssen (UK) and EU Horizon 2020. No shareholdings in pharmaceutical companies. CML sits on the scientific advisory board for Myriad Neuroscience, has received speaker fees from SYNLAB, and consultancy fees from UCB. JM, WLEW, TRP and GSD declare no financial conflict of interest.Funding StatementThis study was funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. WLEW is supported by the National University of Singapore President's Graduate Fellowship. TRP is supported by the MRC (UKRI) as part of a New Investigator Research Grant [MR/W028018/1]. GSD is supported by the Ministry of Education, Singapore, under its Academic Research Fund Tier 3 Award (MOE2017-T3-1-002). All analyses were supported by: King's College London. (2023). King's Computational Research, Engineering and Technology Environment (CREATE). Retrieved May 24, 2023, from https://doi.org/10.18742/rnvf-m076Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). No project-specific ethical approval is needed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUK Biobank data used are available to all bona fide researchers for health-related research that is in the public interest, subject to an application process and approval criteria. Study materials are publicly available online at http://www.ukbiobank.ac.uk.